

研究成果の刊行に関する一覧表

書籍 なし

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
松井尚子、 田中恵子、 和泉唯信	Stiff-person syndrome, Progressive encephalomyelitis with rigidity and myoclonus	日本臨床免疫性神経疾患(第2版)	80(増刊5)	355-360	2022
清水優子	妊娠・授乳期の多発性硬化症・視神経脊髄炎スペクトラム障害(NMOSD)の免疫治療	神経内科	96(4)	402-410	2022
清水優子	免疫性神経疾患(第2版)―基礎・臨床の最新知見―IX. トピックス・今知りたいこと妊娠・授乳中の免疫性神経疾患の治療方針	日本臨床	80(増刊5)	556-563	2022
清水優子	多発性硬化症診療の最新エビデンスと課題-多発性硬化症の妊娠、出産にかかわる諸問題と対処法	医学と薬学	79(4)	473-179	2022
Kuwabara S, Suichi T.	Validation of the 2021 EAN/PNS diagnostic criteria for chronic inflammatory demyelinating polyneuropathy.	J Neurol Neurosurg Psychiatry.	93(12)	1237-1238	2022
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S,	Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis.	J Neurol Neurosurg Psychiatry.	94(6)	467-473	2023

Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda	Impact of Early Treatment with Intravenous High-Doses Methylprednisolone for Ocular Myasthenia Gravis.	Neurotherapeutic	20(2)	518-52	2023
Uzawa A, Ozawa Y, Yasuda M, Onishi Y, Akamine H, Kuwabara S.	Minimal symptom expression achievement over time in generalized myasthenia gravis.	Acta Neurol Belg.		in press	2023
Akamine H, Uzawa A, Kojima Y, Ozawa Y, Yasuda M, Onishi Y, Kuwabara S	Role of soluble forms of follicular helper T-cell membrane molecules in the pathogenesis of myasthenia gravis.	J Neuroimmunol.	375	578014	2023
Kojima Y, Uzawa A, Ozawa Y, Yasuda M, Onishi Y, Akamine H, Kawaguchi N, Himuro K, Noto Y I, Mizuno T, Kuwabara S.	Serum pentraxin 3 concentration correlates with disease severity in patients with myasthenia gravis.	Clin Neurol Neurosurg	220	107371.	2022
Kojima Y, Shibuya K, Uzawa A, Kano H, Nakamura K, Yasuda M, Suzuki YI, Tsuneyama A, Suichi T, Ozawa Y, Misawa S, Noto Y, Mizuno T, Kuwabara S.	Decreased initial compound muscle action potential amplitudes in myasthenia gravis	Neurology and Clinical Neuroscience.	10(5)	245-251	2022
Yasuda M, Uzawa A, Ozawa Y, Kojima Y, Onishi Y, Akamine H, Kuwabara S.	Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis.	Scand J Immunol.	95(2)	e13122.	2022
Suichi T, Misawa S, Sekiguchi Y, Shibuya K, Nakamura K, Kano H, Aotsuka Y, Otani R, Morooka M, Tsukamoto S, Takeda Y, Mimura N, Ohwada C, Sakaida E, Kuwabara S.	Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome	Intern Med.	61(17)	2567-2572	2022

Yamazaki H, Matsui N, Takamatsu N, Yoshida T, Fukushima K, Takata T, Osaki Y, Tanaka K, Kubo Y, Izumi Y	Application of ultrasound in a case of eosinophilic fasciitis mimicking stiff-person syndrome	Neuromuscul Disord	32	590-593	2022
Eizo Tanaka , Mitsuru Watanabe , Shoko Fukumoto , Katsuhisa Masaki , Ryo Yamasaki , Takuya Matsushita , <u>Noriko Isobe</u>	Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod	Mult Scler Relat Disord.	Vol.70	(in press)	2023
<u>Uzawa A</u> , Utsugisawa K	Biological therapies for myasthenia gravis.	Expert Opin Biol Ther.	23(3)	253-260.	2023
Murai H, Utsugisawa K, Motomura M, Imai T, <u>Uzawa A</u> , Suzuki S.	The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome.	Clin Exp Neuroimmunol.	14(1)	19-27	2023
<u>Izumi Kawachi</u>	Autoimmunity to glutamate receptor channels	Neurol Clin Neurosci.	Early view	1-8 doi: 10.1111/ncn3.12650	2022
<u>Koike H</u> , Iguchi Y, Sahashi K, Katsuno M.	Neutrophil extracellular traps: From antimicrobial innate immunity to the development of chemotherapy-induced peripheral neuropathy.	eBioMedicine		in press.	2023
<u>Koike H</u> , Nishi R, Yagi S, Furukawa S, Fukami Y, Iijima M, Katsuno M.	A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis.	Adv Ther	40(1)	25-40	2022
<u>Koike H</u> , Furukawa S, Mouri N, Fukami Y, Iijima M, Katsuno M.	Early ultrastructural lesions of anti-neutrophil cytoplasmic antibody- versus complement-associated vasculitis.	Neuropathology	42(5)	420-429	2022
<u>Koike H</u> , Furukawa S, Mouri N, Fukami Y, Iijima M, Katsuno M.	Dosage effects of PMP22 on nonmyelinating Schwann cells in hereditary neuropathy with liability to pressure palsies.	Neuromuscul Disord	32(6)	503-511	2022
<u>Koike H</u> , Nishi R, Furukawa S, Mouri N, Fukami Y, Iijima M, Katsuno M.	In vivo visualization of eosinophil secretion in eosinophilic granulomatosis with polyangiitis: An ultrastructural study.	Allergol Int	71(3)	373-382	2022

Fukami Y, <u>Koike H</u> , Katsuno M.	Current perspectives on the diagnosis, assessment, and management of vasculitic neuropathy.	Expert Rev Neurother	22(11-12)	941-952	2022
Fukami Y, <u>Koike H</u> , Iijima M, Mouri N, Nishi R, Katsuno M.	Role of complement components in vasculitic neuropathy associated with systemic lupus erythematosus and rheumatoid arthritis.	Muscle Nerve	66(2)	175-182.	2022
Wako S, Ikeguchi R, Toda K, Kobayashi M, Miyata R, Kuramochi H, Ichihara A, <u>Shimizu Y</u> , Kitagawa K	Characteristic cerebrospinal fluid findings in immune checkpoint inhibitor-related peripheral neuropathy: A case report	Journal of Neuroimmunology	374	Epub (JAN15)	2023
Oshima R, Ikeguchi R, Wako S, Mizuno T, Abe K, Nitta M, Muragaki Y, Kawamata T, Masui K, Yamamoto T, Shibata N, <u>Shimizu Y</u> , Kitagawa K	IgG4-related brain pseudotumor mimicking CNS lymphoma. A case report	Neuropathology	42	526-533	2022
Negishi N, Ikeguchi R, So H, Kobayashi M, Nitta M, Masui K, Nakamichi K, Takahashi K, Ishida H, Kawamata T, Shibata N, <u>Shimizu Y</u> , Kitagawa K.	Successful treatment of progressive multifocal leukoencephalopathy that developed 21 years after renal transplantation: A case report	Neuroimmunology Reports	2	100113	2022
<u>Shimizu Y</u> .	Monoclonal antibody treatment for multiple sclerosis and neuromyelitis optica spectrum disorder: An update.	Clinical and Experimental Neuroimmunology	13	131-132	2022
<u>Sonoo M</u>	Recent advances in neuroanatomy: The myotome update.	J Neurol Neurosurg Psychiatry		in print	2023
Mizoi Y, Ikeda K, <u>Sonoo M</u> , Hatanaka Y, Yamamoto T	Markedly Prolonged Compound Muscle Action Potential Duration in a patient with Coronavirus Disease 2019 related Critical Illness Myopathy.	Neurol Clin Neurosci		in print	2023
Matsukura K, Hokkoku K, Mukai T, Oishi C, Kanbayashi T, Takahashi T, <u>Sonoo M</u>	Tibial nerve SEPs in diagnosing lumbar spinal stenosis: The utility of segmental evaluation using P15 and N21.	Clin Neurophysiol Pract	8	49-57	2023

Masayuki Tahara, Oeda Tomoko, Kazumasa Okada, Kazuhide Ochi, Hirofumi Maruyama, Hikoaki Fukaura, Kyoichi Nomura, Yuko Shimizu, Ichiro Nakashima, Tatsuro Misu, Atsushi Umemura, Kenji Yamamoto and Hideyuki Sawada	Compassionate open-label use of rituximab following a randomized clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration	Mult Scler 60 Related Disord		103730	2022
Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, Aoki M, <u>Fujihara K</u> , <u>Nakazawa T</u> , <u>Nakashima I</u> .	Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD.	J Neurol Sci.	437	120269	2022
Nakamura M, Ogawa R, Fujimori J, Uzawa A, Sato Y, Nagashima K, Kuriyama N, Kuwabara S, <u>Nakashima I</u> .	Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey.	Mult Scler		Online ahead of print	2023
Yamamoto M, Okuno T, Piao JL, Shimizu M, Miyamoto K, Nukui T, Kinoshita M, Koda T, Haryuni RD, Mochizuki H, Sugimoto T, <u>Nakatsuji Y</u> .	Identification of double-stranded DNA in the cerebrospinal fluid of patients with acute neuromyelitis optica spectrum disorder.	Journal of Clinical Neuroscience	107	129–132	2023
<u>Niino M</u> , Fukumoto S, Okuno T, Sanjo N, Fukaura H, Mori M, Ohashi T, <u>Takeuchi H</u> , Shimizu Y, Fujimori J, Kawachi I, Kira JJ, Takahashi E, Miyazaki Y, Mifune N	Correlation of the symbol digit modalities test with the quality of life and depression in Japanese patients with multiple sclerosis.	Multiple Sclerosis and Related Disorders	57	103427	2022

<u>Niino M</u> , Fukumoto S, Okuno T, Sanjo N, Fukaura H, Mori M, Ohashi T, <u>Takeuchi H</u> , Shimizu Y, Fujimori J, Kawachi I, Kira JI, Takahashi E, Miyazaki Y, Mifune N.	Health-related quality of life in Japanese patients with multiple sclerosis.	Journal of Neurology	270	1011-1018	2023
Miyazaki Y, <u>Niino M</u> , Takahashi H, Nomura T, Naganuma R, Amino I, Akimoto S, Minami N,	Stages of brain volume loss and performance in the Brief International Cognitive Assessment for Multiple Sclerosis	Multiple Sclerosis and Related Disorders	67	104183	2022
Matsumoto Y, Kaneko K, Takahashi T, Takai Y, Namatame C, Kuroda H, Misu T, <u>Fujihara K</u> , Aoki M	Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids	Brain		in pres	2023
<u>Murai H</u> , Utsugisawa K, Motomura M, Imai T, Uzawa A, Suzuki S.	The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome.	Clin Exp Neuroimmunol	14(1)	19-27	2023
Yamasaki H, Futamura N, Funakawa I, Kohara N, Yoshimura S, <u>Motomura M</u>	Two Lambert-Eaton Myasthenic Syndrome Patients with Ameliorated Activities of Daily Living Due to Cholinesterase Inhibitors	Intern Med	61卷7号	1063-1065	2022
Sato, W., D. Noto, M. Araki, T. Okamoto, Y. Lin, H. Yamaguchi, R. Kadowaki-Saga, A. Kimura, Y. Kimura, N. Sato, T. Ishizuka, H. Nakamura, S. Miyake, T. <u>Yamamura</u>	First-in-human clinical trial of the NKT cell-stimulatory glycolipid OCH in multiple sclerosis.	<i>Ther Adv Neurol Dis</i>	16, 10.	1177/175628 64231162153	2023

Yokote H, Miyazaki Y, Toru S, Nishida Y, Hattori T, Niino M, Sanjo N, Yokota T.	High-efficacy therapy reduces subcortical grey matter volume loss in Japanese patients with relapse-onset multiple sclerosis: A 2-year cohort study	Multiple Sclerosis and Related Disorders	67	N/A	2022
Hiroaki Yoshikawa, Yumi Adachi, Yosikazu Nakamura, Nagato Kuriyama, Hiroyuki Murai, Yoshiko Nomura, Yasunari Sakai, Kazuo Iwasa, Yutaka Furukawa, Satoshi Kuwabara, Makoto Matsui, Taskforce of Validation of Evidence-based Diagnosis and Guidelines and Impact on Quality of Life (QOL) in Patients with Neuroimmunological Diseases	Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018	PLoS ONE	17(9):	e0274161	2022
Hiroaki Yoshikawa, Yumi Adachi, Yosikazu Nakamura, Nagato Kuriyama, Hiroyuki Murai, Yoshiko Nomura, Yasunari Sakai, Kazuo Iwasa, Yutaka Furukawa, Satoshi Kuwabara, Makoto Matsui	Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan	BMJ Neurology Open	4	e000291	2022
Hiroaki Yoshikawa	Autoimmunity to acetylcholine receptor channels	Neurology and Clinical Neuroscience	n/a	DOI: <a href="https://doi.org/10.1111/ncn.1312659">https://doi.org/10.1111/ncn.1312659</a>	2022
Hiroaki Yoshikawa	Epidemiological study of myasthenia gravis in Japan	Clinical and Experimental Neuroimmunology	14(1)	13-18	2023